ArticleBMC cancer2025
Liver cancer incidence in Saudi Arabia (2001-2020): decreasing trend.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Liver cancer is a leading cause of cancer mortality and morbidity worldwide. Existing data on the liver cancer burden in Saudi Arabia are limited. Therefore, this study aimed to analyze liver cancer incidence and mortality trends in Saudi Arabia over two decades (2001-2020) and to compare them with the regional and worldwide data. Liver cancer incidence data in Saudi Arabia were collected from the national cancer registry reports for the study period (2001 to 2020). Additionally, global and regional data on liver cancer burden were obtained from the World Health Organization (WHO); the International Agency for Research on Cancer (IARC); and the Global Cancer Observatory website. Saudi Arabia revealed a relatively lower burden of liver cancer compared to global rates. Males showed a decreasing trend in age-standardized incidence rates during the study period, while females displayed steady rates. In 2020, liver cancer incidence in males was nearly doubled compared to females with a male-to-female ratio of 1.8:1. Additionally, significant regional variations in the incidence of liver cancer were observed across the administrative regions in Saudi Arabia. Liver cancer ranked first as a cause of cancer death in Saudi Arabia for the year 2020. This trend extends to the broader Gulf Cooperation Council region that includes Saudi Arabia, Qatar, Kuwait, Oman, Bahrain and United Arab Emirates; with Saudi Arabia experiencing the highest liver cancer mortality rate (5.1 per 100,000 people). In conclusion, this study highlights the importance of gender- and region-specific analysis of liver cancer in Saudi Arabia. While the decline of liver cancer incidence in males is promising, further investigations are needed to understand the underlying causes and maintain observance. The high national mortality rate from liver cancer underscores the need for improved prevention, early detection, and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.